Innovent Biologics Technology Limited (Shanghai R&D Center) clinical trials

A subsidiary of Innovent Biologics, Inc.

The registry lists 7 studies whose lead sponsor is Innovent Biologics Technology Limited (Shanghai R&D Center). 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 11, 2026.

Studies

Recruiting first, then most recently updated. Showing 7 of 7. All Innovent Biologics, Inc. studies →

• This is a Multi-Center Study of IBI3026 in Participants With Locally Advanced, Unresectable or Metastatic Solid TumorsRecruitingNCT07327632Early Phase 1

  Sponsor listed in the registry: Innovent Biologics Technology Limited (Shanghai R&D Center)

• A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMDRecruitingNCT07275840Phase 2

  Sponsor listed in the registry: Innovent Biologics Technology Limited (Shanghai R&D Center)

• A Study of IBI3032 in Chinese Healthy Participants and Participants With Overweight or ObesityCompletedNCT07160400Phase 1

  Sponsor listed in the registry: Innovent Biologics Technology Limited (Shanghai R&D Center)

• Tigulixostat (IBI128) vs Febuxostat in GoutActive, not recruitingNCT07414394Phase 3

  Sponsor listed in the registry: Innovent Biologics Technology Limited (Shanghai R&D Center)

• A Study to Evaluate the Efficacy and Safety of IBI302 inSubjects With Diabetic Macular Edema（DME）Active, not recruitingNCT06908876Phase 2

  Sponsor listed in the registry: Innovent Biologics Technology Limited (Shanghai R&D Center)

• A Study of IBI3032 in Chinese Participants With Overweight or ObesityActive, not recruitingNCT07170319Phase 1

  Sponsor listed in the registry: Innovent Biologics Technology Limited (Shanghai R&D Center)

• A Study of IBI3032 in Chinese Healthy SubjectsCompletedNCT07134127Early Phase 1

  Sponsor listed in the registry: Innovent Biologics Technology Limited (Shanghai R&D Center)